Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can brain imaging unlock the secrets of opioid addiction?

NCT ID NCT07800520

Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

Researchers at Yale University are using PET brain scans with a radioactive tracer called [11C]OMAR to measure CB1 receptor levels in people with opioid use disorder who are stabilized on buprenorphine, compared to healthy controls. The study aims to see if CB1 receptor availability differs between these groups and whether it relates to mood, stress, or relapse risk. Participants will undergo brain imaging and complete questionnaires about depression, anxiety, and stress. This is an early-stage study focused on understanding the brain's role in opioid addiction, not on testing a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[11C]OMAR, a radioactive tracer used in PET brain scans to visualize CB1 receptors
What this could lead to
If this study succeeds, it could clarify how opioid use disorder affects CB1 receptors in the brain, potentially guiding new treatments for opioid dependence and relapse prevention.
What could go wrong
This is an early-phase imaging study with a small number of participants, so findings may not apply broadly. The radioactive tracer involves radiation exposure, and results may not directly lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All * Normal screening bloodwork. * Adequate arterial access for placement of an arterial line and blood sampling per study protocol. OUD Participants: * Diagnosis of opioid use disorder (OUD) according to DSM-5 criteria. * Actively seeking treatment for OUD. * Willingness to initiate opioid agonist therapy (OAT) with buprenorphine. Healthy Controls: * Good general physical health. * No current or past diagnosis of any psychiatric or substance use disorders. Exclusion Criteria: All * Any current major medical condition that, in the opinion of the Principal Investigator, poses a risk for PET procedures. * Prior participation in research studies within the past year that would result in cumulative radiation exposure exceeding annual limits. * Presence of ferromagnetic metal in the body, pacemaker, or other contraindications to MRI. * Positive pregnancy test or current lactation. * History of neurological conditions, including stroke or seizure disorders. OUD Participants * Current or past diagnosis of a serious psychiatric disorder. * Current diagnosis of any substance use disorder other than nicotine or opioids. * Use of any substances within the past 30 days. * Current use of SSRIs or benzodiazepines or use within the past 30 days. * Previous enrollment in the main study. Healthy Controls: * Current or past diagnosis of any psychiatric disorder. * Current diagnosis of any substance use disorder (excluding nicotine). * Use of any substances within the past 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OAT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence thyroid gland oncocytic adenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OAT Opioid-use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Connecticut Mental Health Center, Clinical Neuroscience Research Unit

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.